No Significant PFS Benefit With Axitinib in First-Line Metastatic RCC

Article

The second generation VEGFR inhibitor axitinib did not significantly improve progression-free survival in first-line treatment of patients with metastatic renal cell carcinoma compared with patients treated with sorafenib.

The second generation VEGFR inhibitor axitinib did not significantly improve progression-free survival in first-line treatment of patients with metastatic renal cell carcinoma compared with patients treated with sorafenib.

These results come from a randomized, open-label phase III trial presented earlier this year at the Genitourinary Cancers Symposium. Final results of the study were published online by Thomas E. Hutson, DO, of US Oncology Research, and colleagues in the Lancet Oncology.

The trial included 288 patients with treatment-naive metastatic renal cell carcinoma who were randomly assigned 2:1 to treatment with axitinib (n = 192) or sorafenib (n = 96). At the July 2012 cutoff date, 59% of patients had died or progressed.

No significant difference in median progression-free survival was found between those patients assigned axitinib compared with those assigned sorafenib (10.1 months vs 6.5 months; HR = 0.77; 95% CI, 0.56-1.05).

The researchers did find that median progression-free survival was longer with axitinib in patients with ECOG performance status of 0, but not in patients with performance status of 1. In addition, objective response was more frequent in patients assigned axitinib than with sorafenib.

Serious adverse events occurred in 34% of patients assigned axitinib compared with 25% of patients assigned sorafenib.

In an editorial accompanying the results, Nadia Yousaf, MD, and James Larkin, MD, of Royal Marsden Hospital, London suggested that no efficacy was seen in this patient population because the study was underpowered.

“As the authors acknowledge, the choice of sorafenib as the control can also be criticized as a so-called low bar by comparison with pazopanib or sunitinib, because sorafenib is not generally accepted as first-line standard of care,” they wrote. “Furthermore, in calculation of sample size requirements, the benefit of sorafenib might have been underestimated because earlier studies reported a median progression-free survival of roughly 5 months.”

They went on to point out that although a study with a larger sample size might show a significant benefit for axitinib that with multiple other drugs currently being used for renal cell carcinoma, there are more pressing research issues such as “the optimum scheduling strategies of drugs already approved and expediting of the investigation of truly novel drugs such as those targeting the PD1 receptor, a molecule involved in immune checkpoint signaling.”

Axitinib is currently approved for use in second-line treatment of metastatic renal cell carcinoma.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content